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Abstract
Background: Many aspects of pharmacological treatment of Lyme neuroborreliosis in children, such as choice of
drug, dosage, and duration are subject to intense debates, leading to uncertainties in patients’ parents and
healthcare providers alike. To assess the available evidence for pharmacological treatment for children with
Lyme neuroborreliosis we conducted a systematic review.
Methods: The comprehensive systematic literature search included randomized-controlled trials (RCTs) and
non-randomized studies (NRS) on treatment of Lyme neuroborreliosis in children (age <18 years). Our primary
outcome was neurological symptoms after treatment. Risk of bias was assessed with the Cochrane risk of bias
tools for RCTs and NRS. Quality of evidence was assessed using the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach.
Results: Two RCTs and four NRS were eligible for inclusion. Risk of bias in RCTs and NRS was generally high.
Reporting of studies was generally poor. Regarding the primary outcome neurological symptoms at 1–3 months, no
statistically significant difference could be found in cohort studies between doxycycline and beta-lactam antibiotics. In
two RCTs comparing penicillin G and ceftriaxone, no patient experienced residual neurological symptoms at the last
reported time points. Quality of evidence according to GRADE was judged very low.
Conclusions: Data is scarce and with limited quality. Several issues could not be addressed due to scarcity of
information. No eligible study compared different treatment durations. According to the available evidence, there
seems to be no difference between different antibiotic agents for the treatment of Lyme neuroborreliosis in children
regarding neurological symptoms. We found no evidence that supports extended antibiotic regimes.
Review registration: Systematic review registration: CRD42014008839.
Background
Lyme borreliosis is a tick-borne infectious disease affect-
ing several organ systems including the nervous system
caused by Borrelia burgdorferi sensu lato. It occurs with
an incidence of about 111/100,000 inhabitants in Central
Europe, of which approximately 2–3 % will develop
neurological manifestations [1, 2], based on the large
population-based study from central Germany. A bimodal
pattern with two age peaks can be observed, one in
children aged 5–14 years and one in elderly people
aged 65–74 years [2, 3]. By far the most frequent early
manifestation of Lyme borreliosis is erythema migrans,
although other manifestations of the disease can occur
without dermal signs [4].
Common clinical manifestations of Lyme neuroborre-
liosis in children are cranial nerve palsy and meningitis
[3, 5]. Late manifestations, like myelitis or encephalitis,
are rarely seen in children [6]. Diagnosis is usually based
on clinical presentation, serologic testing and analysis of
cerebrospinal fluid [4].
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The likelihood of a diagnosis of Lyme neuroborreliosis
in adult patients can be evaluated by case definitions re-
garding the available diagnostic results [7, 8]. According
to results of diagnostic tests, likelihood of diagnosis can
be rated as ‘possible’, ‘probable’ or ‘definite’ as proposed
by the European Federation of Neurological Societies
[8, 9]. Unfortunately, no validated case definitions exist
for children. The qualification as a ‘possible’ case re-
quires only the detection of antibodies against Borrelia
burgdorferi in serum, which is reported to occur in ap-
proximately 5 % of otherwise healthy children in en-
demic areas [10]. The case definition of a ‘probable’
Lyme neuroborreliosis requires a confirmed lymphocytic
pleocytosis in the CSF analysis with no other plausible
explanation. The case definition of a ‘definite’ Lyme
neuroborreliosis is determined by the presence of spe-
cific intrathecal antibodies against Borrelia burgdorferi
additional to a conformed lymphocytic pleocytosis in
CSF analysis. In early stages of Lyme neuroborreliosis
in children, an intrathecal synthesis of antibodies against
Borrelia burgdorferi in CSF may be absent [11]. If un-
treated, acute symptoms may vanish in some cases, but
some children with Lyme neuroborreliosis may develop
late manifestations of the musculoskeletal or nervous
systems [12, 13].
Residual symptoms and long term outcomes after
treatment are subjects to debate, as some studies report
cognitive deficits in children with Lyme neuroborreliosis
[14], whereas other studies report normal findings in
neuropsychological tests for children with Lyme neuro-
borreliosis after antibiotic treatment [15].
Choice of drug, route of administration, and duration
of treatment are still a matter of debate [16, 17]. Treat-
ments with multiple antibiotic drugs concomitantly,
antibiotic agents like carbapenems and adjuvant drugs
like hydroxychloroquine and extended antibiotic treat-
ments >28 days are recommended by guidelines from
patient advocacy groups [17]. Extended antibiotic treat-
ments may cause considerable harm, even fatal com-
plications have been reported [18, 19]. Furthermore,
unnecessary extended antibiotic courses contribute to
the growing problem of multidrug-resistant bacteria [20].
Guidelines from scientific societies recommend
treatment for 14–28 days [7, 16, 21]. Recommenda-
tions for such treatments should be based on solid
clinical evidence. We assessed the available evidence
for pharmacological treatments for children with Lyme
neuroborreliosis.
Methods
We searched the databases MEDLINE (via Ovid, from
1950 to 2015), EMBASE (via Scopus, from 1980 to the
present) and the Cochrane Central Register of Con-
trolled Trials for eligible studies. Search strategies are
shown in Additional file 1. No language restrictions
were set. In addition, we searched three trials registers
(www.controlled-trials.com, www.clinicaltrials.gov and
www.who.int/trialsearch/) to identify further published
or unpublished studies or data for completed or on-
going studies.
We included randomized controlled trials (RCTs) and
non-randomized studies (NRSs) evaluating pharmaco-
logical treatment of children (age <18 years) with clinically
diagnosed Lyme neuroborreliosis. Studies were eligible for
inclusion if they reported a comparison of a pharmaco-
logical treatment against another pharmacological treat-
ment, against placebo or against no treatment. Studies
without a comparison group or a population of less than
five patients were excluded.
Diagnosis of Lyme neuroborreliosis was based on the
clinical case definition by Halperin, Kaiser and Mygland
[7–9]. Diagnostic criteria for case definitions were de-
scribed in detail in a protocol for a systematic review on
pharmacological treatment of Lyme neuroborreliosis in
adults [22]. We applied the same methods in this sys-
tematic review regarding pharmacological treatment in
children. Studies regarding patients with ‘Post-Lyme-
Disease’, defined as previously treated patients with per-
sistent symptoms in the absence of evidence for ongoing
infection, were excluded. Any pharmacological treatment,
including combinations of treatments, was considered.
Single agents as well as groups of antibiotics were com-
pared with each other.
Our primary outcome was ‘neurological symptoms
after treatment’. If several time points were reported in a
primary study, data from the last time point was consid-
ered. If data permitted, results were presented for short
term follow-up (1 to 4 months following the start of
treatment) and for long term follow-up (last reported
time point). Secondary outcomes were adverse events,
disability, patient reported outcomes (e.g., quality of life,
pain, fatigue, depression, cognition and sleep), and cere-
brospinal fluid pleocytosis. Any adverse event as defined
and reported by the original authors was considered.
Adverse events were reported as serious adverse events
when they required hospitalization, were life-threatening,
fatal or when reported as serious adverse events by the
original authors.
Firstly, one reviewer (RD) evaluated titles and abstracts
to determine whether the study was possibly eligible.
Secondly, each full text was evaluated independently by
two reviewers (RD, SS or TH) for eligibility. Disagree-
ments were resolved by discussion or with a third reviewer
(JM). Two review authors independently extracted data
from the full texts of included studies using a specifically
developed extraction form, which had been piloted previ-
ously. Data was entered into Review Manager (RevMan
5.3) by one of the reviewers and checked by a second
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reviewer. Discrepancies in data extraction or entry were
resolved by discussion with a third reviewer. Reviewers
were not blinded to study author, journal, or institution.
Risk of bias was assessed by two reviewers independently
using the Cochrane risk of bias (RoB) tools for RCTs and
for NRSs, respectively [23, 24]. According to the recom-
mendations for the Cochrane RoB-tool for NRSs, no stud-
ies assessed as having a ‘critical’ risk of bias were included
in the quantitative data synthesis. We initially planned to
assess the primary outcome ‘neurological symptoms’ as a
continuous outcome. However, the majority of included
studies reported the outcome dichotomized, so the results
are presented accordingly. If neurological symptoms were
reported as continuous or categorical variables, data was
appropriately dichotomized according to the measurement
scales and categories used. Data was analyzed on an
intention-to-treat basis. If this was not possible, data was
used as reported by the primary authors. If data was only
available in graphical format, we thoroughly estimated the
numeric values. Heterogeneity among studies was investi-
gated by using the Chi2 test and I2 test, see protocol for
details [22]. Risk for publication bias was reduced in our
systematic review by ensuring a comprehensive search for
eligible studies including three trial registries. Only a small
set of studies was available for comparisons, so we did not
provide a funnel plot.
Pooling of data and meta-analysis of studies was only
considered among studies with similar design (e.g., RCTs
were only combined with other RCTs) and limited het-
erogeneity. Combined estimates were not provided for
studies with considerable differences in the included
population or differences regarding interventions. We
planned to provide estimates of treatment effects on a
fixed effect model. We planned to calculate pooled risk
ratios and 95 % confidence interval across comparable
studies using Review Manager (RevMan 5.3). Subgroup
analyses were planned to consider dosage of drugs, geo-
graphical origin of studies, length of treatment, and like-
lihood of diagnosis. Sensitivity analyses were planned to
assess the effect of risk of bias in included studies. We
used the Grading of Recommendations Assessment, De-
velopment and Evaluation (GRADE) approach to assess
the quality of evidence for each outcome [25].
Results
The search identified 5779 bibliographic records after re-
moval of duplicates, of which 5735 were excluded, and 44
full-text articles were retrieved for detailed examination
(Fig. 1). We identified six eligible studies, two RCTs
[26, 27], and four NRS (one prospective cohort study [28]
and three retrospective cohort studies [29–31]. Reasons for
exclusion of the remaining 38 studies are listed in Fig. 1.
One retrospective cohort study reported on patients with
‘probable’ Lyme neuroborreliosis [30], all other studies in-
cluded patients according to the ‘possible’ case definition.
The included studies compared different interventions,
which are summarized in Table 1. We merged interven-
tion groups with betalactam antibiotics together to be
compared to patients treated with doxycycline. Three
studies compared different kinds of betalactam antibi-
otics [26–28], one evaluated betalactam antibiotics and
doxycycline [30], whereas two studies investigated a var-
iety of interventions [29, 31].
Fig. 1 PRISMA flow chart
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Millner 1995 41 possible penicillin G 300,000-375,000 IU/kg, ceftriaxone 100 mg/kg,
sample size of groups not reported
14 days Tertiary care
center
Austria
Müllegger 1991 23 possible penicillin G 400,000-500,000 IU/kg (n = 11),
ceftriaxone 75–93 mg/kg (n = 12)








Thorstrand 2002 203 probable ceftriaxone 100 mg/kg, maximum 2 g (n = 109),
penicillin 100 mg/kg (n = 53), doxycycline 4 mg/kg,
maximum 200 mg (n = 22), cefotaxime 100 mg/kg (n = 19)
10 days Tertiary care
center
Sweden
Bingham 1995 19 possible ceftriaxone, amoxicillin, erythromycin, penicillin, doxycycline,
steroids, aciclovir or no treatment. Dosages not stated.





9 possible ceftazidim+ doxycycline (n= 5), amoxicillin + doxycycline (n= 1),
ceftazidim+ amoxicillin (n= 1), doxycycline (n= 1), ceftazidim (n= 1)
3–6 weeks Tertiary care
center
Poland
Fig. 2 Risk of bias in randomized controlled trials
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The most frequent interventions were penicillin G
(five studies), ceftriaxone (four studies) and doxycycline
(two studies). No eligible studies evaluating treatment
with hydroxychloroquine, azithromycin, minocycline or
carbapenem antibiotics were identified. Length of treat-
ment was 14 days in both RCTs. NRS showed consider-
able differences regarding length of treatment ranging
from 10 to 30 days.
All studies had serious risk of bias issues (Fig. 2). RCTs
suffered from poor reporting on allocation concealment,
random sequence generation and lack of blinding. Risk
of bias and poor reporting were even more problematic
in NRS (Fig. 3). Sample bias, baseline confounding and
blinding of outcome assessment were major issues in all
studies. Interventions were described insufficiently in
three NRS [28, 29, 31]. All expect one NRS had ‘critical’
overall risk of bias [30]. Selective reporting cannot be
ruled out in any RCT or NRS, as no corresponding pro-
tocols were available.
Data on neurological symptoms after pharmacologic
treatment for the comparison of betalactam antibiotics
against doxycycline could be extracted from three NRS
[30, 31]. As two of these studies had critical risk of bias,
data were not pooled [31]. Estimates from all studies had
wide confidence intervals and showed no statistically
significant difference between the two treatments (Fig. 4).
No data regarding our secondary outcomes could be
extracted.
Data on neurological symptoms after pharmacologic
treatment for the comparison of penicillin G against cef-
triaxone could be extracted from one RCT and two NRS
[26, 28, 30]. No estimate could be provided for the RCT,
as no patients had neurological symptoms at last reported
time point after treatment. The NRS could not be pooled
due to critical risk of bias. Estimates from single studies
had wide confidence intervals due to small sample sizes
and showed no statistically significant differences between
treatments (Fig. 5). Millner and colleagues compared
treatment with penicillin G and ceftriaxone in an RCT,
but did not provide data on sample sizes in treatment
groups, so study data could not be combined with that of
Müllegger and colleagues [26, 27]. The authors state that
at last reported follow up (12 months after treatment) no
participant had neurological symptoms in either treatment
Fig. 3 Risk of bias in non-randomized studies
Fig. 4 Forest-plot for the comparison of betalactam antibiotics versus doxycycline for residual neurological symptoms in non-randomized studies
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group. Millner and colleagues reported no adverse events
for the penicillin G group, but moderate allergic skin rash
(n = 1), elevated liver enzymes (n = 2), and asymptomatic
bile concrements (n = 6) in the ceftriaxone group. Bile
concrements were actively sought via sonography in the
ceftriaxone group but not in the penicillin G group, which
diminishes comparability. Adverse events reported in
other studies could not be attributed to an intervention,
so no comparison could be performed. No data regarding
other secondary outcomes could be extracted.
One retrospective cohort study with critical risk of
bias reported data on neurological symptoms after treat-
ment with combinations of antibiotic treatments against
single drugs. The difference between these two heteroge-
neous groups was not statistically significant (RR 4.44,
95 % CI 0.96-20.50, p = 0.0558, Fig. 6).
None of our pre-planned subgroup and sensitivity
analyses considering dose, geographical origin, length
of treatment, likelihood of diagnosis, or risk of bias
were possible for any comparison due to the paucity
of data.
The quality of evidence according to GRADE is pre-
sented in Tables 2, 3 and 4 [25]. Quality of evidence in
RCTs as well as in NRS was very low, considerably low-
ering the overall confidence in the presented results.
The reasons for down-rating the quality besides risk of
bias in RCTs were risk of bias and imprecision, in NRS
risk of bias, indirectness, and imprecision.
Discussion
A strength of this review is the comprehensive search of
the available literature, including three databases for
clinical trials and screening the reference list of included
studies, minimizing the risk of bias in study selection.
Due to the small number of studies included in these
meta-analyses and considerable risk of bias, only limited
conclusions can be drawn from them. We were unable
to assess publication biases due to the low number of
available studies for each of the comparisons.
Literature on pharmacological treatment of Lyme neu-
roborreliosis in children is scarce and with very limited
quality. Most of the available studies were performed
several decades ago when pharmacologic treatment was
less rigorously assessed as it would be performed today
in case of new drugs or indications.
The available evidence is insufficient to identify rele-
vant differences between the evaluated antibiotics. How-
ever, due to small sample sizes and resulting imprecision
in eligible studies, clinically relevant differences between
treatments cannot be excluded.
Different strains of Borrelia burgdorferi show different
patterns of geographical distribution [32]. Although five of
six included studies were performed in Europe, results
from this review may be also applicable in regions where
distribution of these strains is different, as in North Amer-
ica, since neurological manifestations differ in frequency
but not in clinical presentation. Only one study used the
‘probable’ case definition, whereas the other studies ap-
plied diagnostic criteria consistent with the ‘possible’ case
definition. As this category often lacks CSF analysis, it is
more broad compared to the other case definitions and
therefore less specific. More ‘false positive’ patients may
be included in studies using the “possible” case definition,
probably diminishing treatment effects.
Fig. 5 Forest-plot for the comparison of penicillin G versus ceftriaxone for residual neurological symptoms
Fig. 6 Forest-plot for the comparison of combinations of antibiotic treatments versus single drugs on residual neurological symptoms
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Currently an ongoing Cochrane review evaluates
pharmacologic treatments for Lyme neuroborreliosis
[33]. As treatment of Lyme neuroborreliosis in children
is not the focus of the ongoing Cochrane review, applic-
ability of its results on a pediatric population may be
low.
Prognosis of Lyme neuroborreliosis in children after
treatment appears to be good, irrespective of the anti-
biotic regimen studied in these trials. Unfavorable out-
comes or poor treatment responses were infrequent
regardless of which antibiotic was used. This is illus-
trated by the wide confidence intervals in pooled esti-
mates due to paucity of respective unfavorable events.
Interpreting a limited body of evidence and drawing
implications for clinical practice is difficult. No statistically
significant difference was found between beta-lactam anti-
biotics and doxycycline regarding neurological symptoms
after treatment. However, a relevantly lower rate of neuro-
logical symptoms for either drug cannot be excluded due
to wide confidence intervals. Unfortunately, no data on
adverse events were reported for this comparison, so we
are unable to provide evidence-based conclusions regard-
ing drug safety.
Doxycycline and beta-lactam antibiotics are recom-
mended as alternative treatments by many guidelines, al-
though use of doxycycline is usually not recommended for
children <9 years because of the potential for impairing
dental development [7, 16].
No statistically significant difference was found be-
tween penicillin G and ceftriaxone regarding neurological
symptoms after treatment. Again, a relevantly lower rate
of neurological symptoms for either drug cannot be ex-
cluded due to wide confidence intervals. Adverse events
were only reported for children treated with ceftriaxone in
one study (n = 9), but confidence in this result is rather
low. Severity of these reported adverse events was gen-
erally mild and therefore may only partially influence
treatment choice. Concordant with these findings, both
penicillin G and ceftriaxone are recommended for
treatment of Lyme neuroborreliosis in children by sev-
eral guidelines [7, 16, 21].
No statistically significant difference was found between
combination of antibiotics and single drugs. Confidence in
this result is very low, as data was only reported in one
retrospective cohort study with a small sample size (n = 9)
with heterogeneous treatments, follow-up periods and
critical risk of bias issues. Therefore, no convincing evi-
dence for combination of antibiotics being superior to
treatments with single antibiotics could be identified.
This is in contrast with recommendations for combin-
ation treatments from guidelines developed by patient
advocacy groups [17], but is in agreement with recom-
mendations of guidelines from scientific societies [16].
This finding is also in concordance with the evidence
from available studies on treatment of Lyme neurobor-
reliosis in adults [34].
Table 2 GRADE evidence table for the comparison betalactam antibiotics vs. doxycycline for children with Lyme neuroborreliosis
Quality assessment № of patients Effect Quality
№ of
studies

















abaseline confounding, selected patients, lack of blinding, interventions insufficiently described
bheterogeneous interventions, interventions not clearly described
csmall sample size, optimal information size not met
Table 3 GRADE evidence table for the comparison penicillin vs. ceftriaxone for children with Lyme neuroborreliosis
Quality assessment № of patients Effect Quality
№ of studies Study design Risk of bias Inconsistency Indirectness Imprecision Penicillin Ceftriaxone Relative
(95 % CI)
Neurological symptoms at last reported time point
1 randomised
trials
seriousa not serious not serious very seriousb 0/11 (0.0 %) 0/12 (0.0 %) not estimable ⨁◯◯◯ VERY
LOW
Neurological symptoms at last reported time point
2 observational
studies
very seriousc not serious seriousd seriouse 2/55 (3.6 %) 4/28 (14.3 %) not pooled ⨁◯◯◯ VERY
LOW
ano blinding, randomisation and allocation concealment not stated appropriately, selective outcomes reporting cannot be excluded
bvery small sample size, optimal information size not met
cbaseline confounding, selected patients, lack of blinding, interventions insufficiently described
dheterogeneous interventions, interventions not clearly described
esmall sample size, optimal information size not met
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However, besides the very low quality of the available
evidence and the lack of recent studies, it remains
noteworthy for which interventions no evidence from
eligible studies could be found at all. No studies com-
paring extended antibiotic treatments to treatments of
10–21 days could be found. No eligible studies evaluating
treatment with macrolide antibiotics, antimalarial drugs
or carbapenems in children with Lyme neuroborreliosis
could be identified. The guideline recommendations for
these treatment regimens from patient advocacy groups
are not based on any published evidence [17].
As the provided estimates suffer from considerable im-
precision, it is likely that results of future clinical trials
on this topic will change the presented results. Based on
the available evidence, most questions arising in clinical
practice remain unanswered.
One issue of considerable interest is whether oral
treatment with doxycycline may be sufficient to treat
early forms of Lyme neuroborreliosis including facial
palsy with lymphocytic pleocytosis in children >8 years.
No studies evaluated extended antibiotic treatment re-
gimes. As long as such a treatment is not evaluated in a
high quality trial, recommendations favoring such re-
gimes remain ill-founded. The scarcity of high quality
trials and the lack of recent studies is rather surprising.
There is clearly a need for large high quality trials evalu-
ating pharmacological treatments for Lyme neuroborre-
liosis in children. The included population should be
adequately described according to consensus derived
case definitions [35]. Trials should be registered prior to
enrolment of the first patient and use predefined out-
comes. However due to the good clinical results of
present treatments used during the last 30 years in chil-
dren it might be difficult to find a sponsor for large high
quality trials evaluating pharmacological treatments for
Lyme neuroborreliosis in children.
Conclusion
According to the available evidence, there seems to be
no difference between different antibiotic agents for the
treatment of Lyme neuroborreliosis in children regard-
ing neurological symptoms. No eligible study compared
different treatment durations. We found no evidence
that supports extended antibiotic regimes.
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